Can cosentyx cause changes in appetite levels?

Can Cosentyx affect appetite?

Cosentyx (secukinumab) is a monoclonal antibody targeting IL-17A. It is prescribed for psoriasis, psoriatic arthritis, and ankylosing spondylitis. The prescribing information lists common side effects including diarrhea, nausea, and upper respiratory infections, but does not mention appetite changes as a recognized adverse effect.

Does Cosentyx change appetite directly?

The official prescribing information identifies diarrhea and nausea as gastrointestinal side effects. These symptoms can indirectly affect how much food a person feels able to eat. Some patients report altered eating patterns during active periods of these complaints.

Why are companies challenging this patent?

The basic patent for secukinumab, held by Novartis, expires in 2027. Companies such as Samsung Bioepis and Celltrion are preparing biosimilars that are expected to launch once that date is reached. Companies challenge patents to gain early entry into the market.

When does the patent expire?

The core composition-of-matter patent for secukinumab expires March 2027. Composition-of-matter patents usually receive an extension up until 2028 or 2029 under pediatric exclusivity or regulatory data protection periods. [1]

Who makes Cosentyx?

Novartis Pharmaceuticals Corporation is the originator developer and current sole producer. Multiple biosimilar developers are working on replicas that will compete once patent protection ends.

Can biosimilars enter before patent expiry?

Biosimilars do not normally enter before the core patent expires. The 2027 expiration date is the earliest possible date for any legal entry of a biosimilar into the US market.